Cancer, Solid Tumors
Conditions
Brief summary
The purpose of this observational study in France is to evaluate changes in satisfaction with care in participants with solid tumors who transitioned from receiving immunotherapy treatment in the hospital outpatient setting to receiving treatment at home
Interventions
DRUGImmunotherapy
Immune checkpoint inhibitors in approved indications
Sponsors
Bristol-Myers Squibb
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female ≥ 18 years old * Participants whose oncology specialist has already initiated treatment with immune checkpoint inhibitors (ICIs) in the outpatient hospital setting for an advanced solid tumor (as monotherapy or in combination) or as adjuvant therapy, in an indication approved and reimbursed in France * Participants whose oncology specialist has independently of the study defined their eligibility for hospital at home (HAH) before contacting the HAH unit for final admission * Participants who provide oral informed consent to participate in the study
Exclusion criteria
* Participants who have expressed an opposition to their data collection * Participants under guardianship * Participants taking part in an interventional study for cancer treatment with at least one ICI as an investigational drug
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in patient satisfaction on the European Organisation for Research and Treatment of Cancer satisfaction with cancer care core questionnaire (EORTC PATSAT-C33) when transitioning from Outpatient Hospital to Hospital at Home to receive immunotherapy | Participants follow up approximately 24 weeks after transition to treatment at home |
Countries
France
Outcome results
None listed